Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Authors describe the frequency of bone tumours in the shoulder region and the anatomical characteristics of this region, that are important, regarding tumour surgery. Six cases are reported in whom resection was performed for malignant, semimalignant and benign bone tumours. In their material one primary and two secondary chondrosarcomas, one Ewing's sarcoma, one osteoclastoma and one benign chondroblastoma were found. Follow-up range was 3-7 years. In two patients partial and total scapulectomy was performed, in the later the proximal end of the humerus was resected only, in three of them endoprosthesis was given, and in one case the missing bone was replaced with a fibular graft. The function of the limbs was in every case, even in those in which the replacement of the bone segment was not carried out, adequate. Metastases developed in three patients, two of them were lost, one is alive. The rest of the patients was free of tumour at the follow-up.
 ...
PMID:[Limb-preserving resection operations in the management of bone tumors of the shoulder region]. 257 54

This is a case report on a giant cell sarcoma or malignant osteoclastoma of the mammarian gland. Clinical diagnosis of this very rare tumor was of an exulcerating breast carcinoma. Histologically, this tumor shows epulis-like giant cells. Pathogenetically, a metaplasia of stromal cells, and of the glandular epithelium, is discussed. A simple mastectomy with extirpation of the axillary lymph nodes was performed. No metastases were found.
 ...
PMID:[Giant cell sarcoma: a rare breast tumor]. 272 94

The giant-cell tumor (osteoclastoma) is very rare in the head and neck. Its histogenesis, diagnosis and classification are difficult. Although it is considered to be benign, it should be regarded by the clinician as malignant, because of its high recurrence rate, potential metastases and the difficulty of total removal. We performed an extended radical mastoidectomy in a 42-year-old woman with such a tumor of the petrous bone, primarily to prevent such complications.
 ...
PMID:[A case of osseous giant cell tumor of the temporal bone and tympanum]. 336 Jun 34

A giant cell tumor of bone appeared in a lymph node of a 21-year-old man at the time of local recurrence in its original location in the distal femur, prior to metastasizing the lung. Following a wide resection, the lesion did not recur, but asymptomatic pulmonary metastases were discovered. DNA analysis by flow cytometry demonstrated identical patterns in the primary and initial recurring lesions, as well as in the pulmonary metastases, which suggests that this technique may be a valuable diagnostic tool for assessing the potential aggressiveness of giant cell tumor of bone. Giant cell tumor of bone is rarely associated with metastases of any kind. Rare instances of pulmonary spread have been reported in the literature. Lymph node involvement is even more unusual. Only two such cases have been previously reported.
 ...
PMID:Giant cell tumor of bone with pulmonary and lymph node metastases. A case report. 373 11

The presence of giant cells in a tumour does not justify the diagnosis of osteoclastoma. Although some may dispute the existence of the osteoclastoma, its radiological and microscopic features are sufficiently typical to justify its classification as a separate tumour. It is believed that the tumour arises from proliferating capillary buds from cells which have the potential of becoming collagenoblasts, osteoblasts, chondroblasts or histiocytes. It is suggested that the giant cells are made up of merged matrix cells. Since it is believed that the true osteoclastoma is always malignant (although it is late to metastasize) and since it has a high potential for recurrence, initial treatment should be radical and should consist of block excision or amputation.
 ...
PMID:Osteoclastoma. A review of the condition and a report of 5 cases. 663 68

Giant cell tumor of bone is a challenging surgical problem due to its mostly aggressive growth with tendency to recur locally, to develop in rare instances pulmonary metastases without histologic evidence of malignant changes, and due to its potential to dedifferentiate into a frankly malignant tumor in a limited number of patients. It is treated in many different ways because of the difficulties in finding a type of treatment with the best functional results without compromising oncologic results. This paper describes 19 patients with giant cell tumor of bone. Following 19 procedures (including 6 intracapsular resections [curettage]) in 17 patients in our hospital only 2 recurrences (10.5%) occurred, both after curettage. Functional results after curettage without recurrence were favorable. Marginal or wide resections did not result in any recurrence, but were functionally inferior to curettage; an exception to the latter was the resection-arthrodesis of the distal radius in one patient.
 ...
PMID:Giant cell tumor of bone: oncologic and functional results. 799 Apr 80

We studied the value of histopathological grading in determining the prognosis of giant cell tumour (osteoclastoma) and the rate of local and distant recurrences in a consecutive series of 31 patients. We found that grading had no prognostic value. Eighteen patients were treated by intralesional curettage and 13 by wide excision. Ten patients (56%), who were all treated by curettage, had local recurrences, but none of the tumours with wide excision recurred (p < 0.05). Five (16%) had local recurrences as well as distant metastases, usually to the lungs. The recurrences developed later than an average of 12 years after primary treatment in 3 patients. Wide excision and life-long follow up should be considered in the management of these tumours.
 ...
PMID:Local recurrences in giant cell tumour of bone. Long-term follow up of 31 cases. 883 21

Giant cell tumor of bone is a challenging clinicopathologic entity. Despite its benign designation, it has the capacity to recur locally and develop rare pulmonary metastases. Between 1945 and 1991, 104 patients with histologically benign giant cell tumors of bone, 5 of which metastasized to the lung, were treated at the authors' institution. In these cases, histologic materials from the lung were identical to those found in the primary bone lesion. The primary bone lesions were treated with local curettage (3), wide resection (1), and wide resection with prosthesis placement (1). The patients were observed for a mean of 12.6 years (range, 5-38 years). Four of the 5 patients experienced local recurrences (average time interval, 34 months), with 3 patients experiencing 2 or more recurrences. The average time to lung metastasis was 23 months; 1 patient presented initially with pulmonary findings. Four patients underwent surgical resection of pulmonary metastases. All 4 patients are alive with no disease progression, despite incomplete pulmonary resections in 2 patients. Locally aggressive disease and multiple recurrences appear to be risk factors for pulmonary metastases in benign giant cell tumor of bone. Pulmonary metastases occurred within the first few years after discovery of primary bone tumors. Radiographs and computed tomographs of the chest are recommended to rule out this complication in patients with local recurrences. Resection of pulmonary metastasis is recommended. Long term survival is not incompatible with persistent pulmonary lesions.
 ...
PMID:Giant cell tumor of bone. Prognosis and treatment of pulmonary metastases. 917 Mar 81

Amputation is commonly performed in an attempt to both treat and diagnose conditions affecting the digits of cats. The records of multiple veterinary diagnostic laboratories were searched to identify submissions of amputated digits from cats. Eighty-five separate submissions were reviewed for diagnosis, age, sex, limb of origin, and digits affected; and the original submitting clinics were surveyed to determine clinical outcome. The Kaplan-Meier product-limit method was used to determine the disease-free interval and survival time. Neoplastic disease was identified in 63 of 85 submissions, with exclusively inflammatory lesions composing the other 22 cases. In 60 (95.2%) of the neoplastic cases, a malignant tumor was identified. Squamous cell carcinoma was the most commonly identified malignant tumor (n = 15; 23.8%) and was associated with a median survival time of 73 days. Other diagnoses included fibrosarcoma (n = 14; 22.2%); adenocarcinoma, likely metastases of a primary pulmonary neoplasm (n = 13; 20.6%); osteosarcoma (n = 5; 7.9%); mast cell tumor (n = 4; 6.3%); hemangiosarcoma (n = 5; 7.9%); malignant fibrous histiocytoma (n = 2; 3.2%); giant cell tumor of bone (n = 2; 3.2%); and hemangioma (n = 2; 3.2%). Giant cell tumor of bone has not been previously described in the digits of cats. Various neoplasms can occur in the digits of cats, and submission of the amputated digit for histopathologic diagnosis is essential to determine the histogenesis and predict the clinical outcome.
 ...
PMID:Diagnoses and clinical outcomes associated with surgically amputated feline digits submitted to multiple veterinary diagnostic laboratories. 1749 Oct 78

Giant cell tumour of bone (GCTB) is a benign bone tumour known for the unpredictable clinical behaviour of recurrences and, in rare instances, distant metastases. It consists of uniformly distributed osteoclastic giant cells in a background of mononuclear rounded and spindle-shaped cells. Cytogenetically, telomeric associations are the most common chromosomal aberrations, which, however, are normally almost exclusively found in high-grade malignancies. GCTB has often been regarded as a polyclonal tumour, but more recently a recurrent specific aberration was reported, which suggests a possible role for disturbed telomere maintenance. Here we further investigate telomere maintenance in GCTB using 19 samples from 19 patients. A combination of immunofluorescence and FISH was performed, applying antibodies directed against promyelocytic leukaemia body-related antigen and hTERT and using telomere peptide nucleic acid probes. The TRAP assay and telomere restriction fragment length analysis were performed for functional detection of telomerase activity and alternative telomere lengthening. Both osteoclastic giant cells and mononuclear cells showed positivity for hTERT and promyelocytic leukaemia body-related antigen. In most mononuclear cells, co-expression was present. The TRAP assay demonstrated heterogeneous telomerase activity, while telomere restriction fragment length analysis showed non-heterogeneous telomere lengths, indicating the absence of alternative telomere lengthening. Confocal microscopy showed stereometric co-localization of nucleolin with promyelocytic leukaemia body-related antigen in association with telomeres in the spindle-shaped cells. hTERT was more diffusely distributed throughout the nucleus. Our results show that GCTB demonstrates remarkable telomere maintenance of activated telomerase and inactivated alternative telomere lengthening in the presence of normal mean telomere restriction fragment lengths. These findings strongly suggest that these aggregates, while activating telomerase, are part of a structural telomere protective-capping mechanism rather than of a telomere-lengthening mechanism. Telomere maintenance could be considered an important key factor in the pathogenesis of GCTB.
 ...
PMID:Telomere biology in giant cell tumour of bone. 1827 85


1 2 3 Next >>